IBJNews

Lilly wins appeals court ruling in Strattera patent case

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, has won an appeals court ruling in its effort to block generic versions of attention-deficit treatment Strattera.

The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on the medicine was invalid. The Federal Circuit remanded the case to the lower court for further proceedings. The patent expires in 2017.

Strattera, known by its chemical name atomoxetine hydrochloride, generated sales of $577 million last year for Lilly. The company had won an order that prevented drugmakers including Mylan Inc. and Teva Pharmaceutical Industries Ltd. from entering the market with a generic version until this appeal was decided.

The other companies seeking to sell copies of the medicine include Sun Pharmaceutical Industries Ltd., Novartis AG’s Sandoz unit, Synthon BV, Iceland’s Actavis Group, Canada’s Apotex Inc., India’s Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Cadila Healthcare Ltd.’s Zydus.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT